Abstract
Brain derived neurotrophic factor (BDNF), a member of the neurotrophin family of structurally related proteins that promote neuronal differentiation and survival during development [1, 2], is a potent modulator of synaptic plasticity [3-7]. Changes in BDNF expression, release and neuromodulatory activity, mediated by both epigenetic and posttranslational mechanisms, have been associated with many pathological conditions and developmental experiences, such as maternal deprivation and environmental enrichment. Much effort has been devoted to studying plasticity in the hippocampus, a structure traditionally associated with learning and memory, yet there is increasing empirical support for the contribution of another structure — the amygdala — to BDNF-induced changes. Because the amygdala is a critical site for emotional memory formation, and many emotional and neurodevelopmental pathologies have been linked to amygdalabased abnormalities, considerable efforts have been devoted to the characterization of its circuitry [8-11]. Here we review the role of BDNF as a biochemical integrator of convergent cellular signals, and as a central driver of neural plasticity . We conclude by emphasizing the importance of characterizing BDNF signaling cascades in behaviorally-relevant networks, to identify potential drug targets for novel therapeutic interventions.
Keywords: Brain-derived neurotrophic factor, plasticity, Learning, memory, psychopathology
Current Molecular Pharmacology
Title: Brain-Derived Neurotrophic Factor: A Dynamic Gatekeeper of Neural Plasticity
Volume: 3
Author(s): Kiriana K. Cowansage, Joseph E. LeDoux and Marie-H. Monfils
Affiliation:
Keywords: Brain-derived neurotrophic factor, plasticity, Learning, memory, psychopathology
Abstract: Brain derived neurotrophic factor (BDNF), a member of the neurotrophin family of structurally related proteins that promote neuronal differentiation and survival during development [1, 2], is a potent modulator of synaptic plasticity [3-7]. Changes in BDNF expression, release and neuromodulatory activity, mediated by both epigenetic and posttranslational mechanisms, have been associated with many pathological conditions and developmental experiences, such as maternal deprivation and environmental enrichment. Much effort has been devoted to studying plasticity in the hippocampus, a structure traditionally associated with learning and memory, yet there is increasing empirical support for the contribution of another structure — the amygdala — to BDNF-induced changes. Because the amygdala is a critical site for emotional memory formation, and many emotional and neurodevelopmental pathologies have been linked to amygdalabased abnormalities, considerable efforts have been devoted to the characterization of its circuitry [8-11]. Here we review the role of BDNF as a biochemical integrator of convergent cellular signals, and as a central driver of neural plasticity . We conclude by emphasizing the importance of characterizing BDNF signaling cascades in behaviorally-relevant networks, to identify potential drug targets for novel therapeutic interventions.
Export Options
About this article
Cite this article as:
Cowansage K. Kiriana, LeDoux E. Joseph and Monfils Marie-H., Brain-Derived Neurotrophic Factor: A Dynamic Gatekeeper of Neural Plasticity, Current Molecular Pharmacology 2010; 3 (1) . https://dx.doi.org/10.2174/1874467211003010012
DOI https://dx.doi.org/10.2174/1874467211003010012 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional Neuroimaging of Sleep Disorders
Current Pharmaceutical Design Identification and Detection of Transmissible Spongiform Encephalopathies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Donepezil: An Important Prototype to the Design of New Drug Candidates for Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry Propofol Inhibits Caspase-3 in Astroglial Cells: Role of Heme Oxygenase-1
Current Neurovascular Research A Comparison Between Quetiapine and Aripiprazole for Treatment of Schizophrenia: A Double Blind Contrast
Current Psychopharmacology The Potential Use of Hormone-Based Therapeutics for the Treatment of Alzheimers Disease
Current Alzheimer Research Cell Microencapsulation Implants into the Central Nervous System
Recent Patents on Nanomedicine Review on Plants with Traditional Uses and Bio-activity against Hair Graying
Current Traditional Medicine A Study of Tryptophan Metabolism via Serotonin in Ventricular Cerebrospinal Fluid in HIV-1 Infection Using a Neuroendoscopic Technique
Current HIV Research A Dual Mechanism Linking NGF/proNGF Imbalance and Early Inflammation to Alzheimer's Disease Neurodegeneration in the AD11 Anti-NGF Mouse Model
CNS & Neurological Disorders - Drug Targets Vascular Disease and Risk Factors in Chronic Kidney Disease
Vascular Disease Prevention (Discontinued) Natural Products Triggering Biological Targets- A Review of the Anti-Inflammatory Phytochemicals Targeting the Arachidonic Acid Pathway in Allergy Asthma and Rheumatoid Arthritis
Current Drug Targets Current Insights of Inhibitors of p38 Mitogen-Activated Protein Kinase in Inflammation
Medicinal Chemistry Structural Preferences of Neuroprotective S14G-Humanin Peptide Analyzed by Molecular Modeling and Circular Dichroism
Protein & Peptide Letters Prasugrel: A Novel Antiplatelet Therapy for Acute Coronary Syndromes
Recent Patents on Cardiovascular Drug Discovery Role of TREM2 in Alzheimer's Disease and its Consequences on β- Amyloid, Tau and Neurofibrillary Tangles
Current Alzheimer Research Small Heat Shock Proteins (sHSPs) As Potential Drug Targets
Current Pharmaceutical Biotechnology Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design Methods and Compositions for Amplification and Detection of microRNAs (miRNAs) and Noncoding RNAs (ncRNAs) Using the Signature Sequence Amplification Method (SSAM)
Recent Advances in DNA & Gene Sequences (Discontinued) Effects of Physical Exercise on Depressive Symptoms and Biomarkers in Depression
CNS & Neurological Disorders - Drug Targets